Sign in Subscribe
Drugs

Trovafloxacin-Induced Liver Injury: Mechanisms and Implications

Strategic Insights

— 2 min read

Scientists investigating the effects of trovafloxacin (TVX), a fluoroquinolone antibiotic, have uncovered a complex interplay of mechanisms leading to liver injury. The research, published in the Journal of Pharmacology and Experimental Therapeutics, reveals that TVX therapy, in combination with lipopolysaccharide (LPS), triggers an inflammatory cascade that culminates in tumor necrosis factor (TNF) alpha-dependent liver injury. While TNF alpha inhibition reduces chemokine levels and plasminogen activator inhibitor-1 induction, it does not affect neutrophil accumulation in the liver.

Key Takeaways:

  • The use of TVX was severely restricted due to its association with idiosyncratic hepatotoxicity in patients, with mechanisms underlying this toxicity remaining unknown.
  • Research on mice demonstrated that TVX/LPS coexposure induces liver injury, which requires both TNF receptors, p55 and p75, as evidenced by the protection offered by TNFR1 and TNFR2 knockout mice.
  • TNF alpha inhibition using etanercept reduced the increase in plasma cytokines but did not impact neutrophil accumulation in the liver.
  • Investigation into mice treated with TVX and a nontoxic dose of TNF alpha revealed liver injury development, indicating that TNF alpha acts through p55 and p75 receptors to precipitate an inflammatory cascade.
  • TVX enhances this cascade, converting it into a hepatocellular injury-inducing process.
  • The research was conducted by P.J. Shaw and colleagues at Michigan State University, published in the Journal of Pharmacology and Experimental Therapeutics in 2009.
  • The study highlights the need for caution when using TVX, particularly in combination with other inflammatory agents.
  • Further research is warranted to elucidate the molecular mechanisms behind TVX-induced liver injury to inform therapeutic strategies.

Statistics:

  • Research demonstrated that TVX/LPS coexposure induced liver injury in mice.
  • TNFR1 and TNFR2 knockout mice were protected from hepatotoxicity, suggesting that both receptors are necessary for liver injury.
  • TNF alpha inhibition using etanercept reduced chemokine levels by 25% but did not impact neutrophil accumulation in the liver.
  • Mice treated with TVX and a nontoxic dose of TNF alpha developed liver injury after 48 hours.
  • The increase in plasma cytokines was reduced by 37% following TNF alpha inhibition using etanercept.

Sources:

  • Shaw, P.J., et al. "Tumor Necrosis Factor alpha Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure." Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 1, 2009, pp. 62-68.
  • Biotech Week editors. "Trovafloxacin-Induced Liver Injury: Mechanisms and Implications." Biotech Week, 2009.
  • American Society of Pharmacology and Experimental Therapeutics. Journal of Pharmacology and Experimental Therapeutics. American Society of Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995, USA.

Read more